1. Recent Articles

    1. Epidemiological analysis of childhood cancer in Japan based on population-based cancer registries, 1993-2009.

      Epidemiological analysis of childhood cancer in Japan based on population-based cancer registries, 1993-2009.

      Jpn J Clin Oncol. 2017 Mar 17;:1-4

      Authors: Ishihara H, Ohno Y, Fujii M, Hara J, Soda M

      Abstract Background: There are few recent data on trends in childhood cancer incidence using population-based cancer registries in Japan. Methods: This study comprised 6110 reported cases of patients aged 0-14 years who were diagnosed as having primary cancer between 1993 and 2009.

      Read Full Article
    2. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    3. Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo.

      Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo.

      Front Neurosci. 2017;11:116

      Authors: Sun J, Wang D, Guo L, Fang S, Wang Y, Xing R

      Abstract Background: Neuroblastoma is the most common extracranial tumors in children. At present about the true etiology of neuroblastoma is unclear and many studies have tried to find effective treatments for these primary malignant tumors.

      Read Full Article
    4. Topotecan-Vincristine-Doxorubicin in Stage 4 High Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid Cojec - a SIOPEN Study.

      Topotecan-Vincristine-Doxorubicin in Stage 4 High Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC - a SIOPEN Study.

      Cancer Res Treat. 2017 Mar 21;:

      Authors: Amoroso L, Erminio G, Makin G, Pearson AD, Brock P, Valteau-Couanet D, Castel V, Pasquet M, Laureys G, Thomas C, Luksch R, Ladenstein R, Haupt R, Garaventa A, SIOPEN Group

      Read Full Article
      Mentions: SIOPEN
    5. Childhood cancer in small geographical areas and proximity to air-polluting industries.

      Childhood cancer in small geographical areas and proximity to air-polluting industries.

      Environ Res. 2017 Mar 16;156:63-73

      Authors: Ortega-García JA, López-Hernández FA, Cárceles-Álvarez A, Fuster-Soler JL, Sotomayor DI, Ramis R

      Abstract AIM: Pediatric cancer has been associated with exposure to certain environmental carcinogens. The purpose of this work is to analyse the relationship between environmental pollution and pediatric cancer risk.

      Read Full Article
    6. Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Pediatr Blood Cancer. 2017 Mar 10;:

      Authors: Adams M, Traunecker H, Doull I, Cox R

      Abstract High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors.

      Read Full Article
    7. Organ motion in pediatric high-risk neuroblastoma patients using four-dimensional computed tomography.

      Organ motion in pediatric high-risk neuroblastoma patients using four-dimensional computed tomography.

      J Appl Clin Med Phys. 2017 Jan;18(1):107-114

      Authors: Kannan S, Teo BK, Solberg T, Hill-Kayser C

      Abstract PURPOSE/OBJECTIVE(S): High-risk neuroblastoma (HR-NBL) requires multimodality treatment, including external beam radiation of the primary tumor site following resection.

      Read Full Article
    8. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus

      Alerts Cancer Therapy: Preclinical Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus Mohanraj Ramachandran , Di Yu , Matheus Dyczynski , Sathishkumar Baskaran , Lei Zhang , Aleksei Lulla , Valeria Lulla , Sirle Saul , Sven Nelander , Anna Dimberg , Andres Merits , Justyna Leja-Jarblad and Magnus Essand Mohanraj Ramachandran PDF Abstract Background: Glioblastoma multiforme and high-risk neuroblastoma are cancers with poor outcome. Immunotherapy in the form of neurotropic oncolytic viruses is a promising therapeutic approach for these malignancies. Here we evaluate the oncolytic capacity of the neurovirulent and partly IFNβ-resistant Semliki Forest virus (SFV)-4 in glioblastoma multiformes ...

      Read Full Article
    9. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.

      Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.

      J Cancer Res Clin Oncol. 2017 Mar 11;:

      Authors: Cai J, Pan C, Tang Y, Chen J, Zhou M, Li B, Xue H, Shen S, Gao Y, Zhang A, Tang J

      Read Full Article
    10. Effects of a combined physical and psychosocial intervention program for childhood cancer patients on quality of life and psychosocial functioning: results of the QLIM randomized clinical trial.

      Effects of a combined physical and psychosocial intervention program for childhood cancer patients on quality of life and psychosocial functioning: results of the QLIM randomized clinical trial.

      Psychooncology. 2016 07;25(7):815-22

      Authors: van Dijk-Lokkart EM, Braam KI, van Dulmen-den Broeder E, Kaspers GJ, Takken T, Grootenhuis MA, Streng IC, Bierings M, Merks JH, van den Heuvel-Eibrink MM, Veening MA, Huisman J

      Read Full Article
    11. Bronchiectasis following treatment for high-risk neuroblastoma: A case series

      High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors. This report outlines a case series of six patients who developed a chronic productive cough following treatment for HR neuroblastoma.

      Read Full Article
    12. An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      Pediatr Dev Pathol. 2017 Jan-Feb;20(1):38-43

      Authors: Parsons LN, Gheorghe G, Yan K, Simpson P, Jarzembowski JA

      Abstract Neuroblastoma is a common malignant tumor of childhood. Accurate bone marrow (BM) evaluation for metastatic tumor is essential; however, no standardized pathologic workup exists for staging BMs.

      Read Full Article
      Mentions: Staging Bone Marrow
    13. The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      Aging (Albany NY). 2017 Mar 08;:

      Authors: He J, Wang F, Zhu J, Zhang Z, Zou Y, Zhang R, Yang T, Xia H

      Abstract TP53, a tumor suppressor gene, plays a critical role in cell cycle control, apoptosis, and DNA damage repair. Previous studies have indicated that the TP53 gene Arg72Pro (rs1042522 C>G) polymorphism is associated with susceptibility to various types of cancer.

      Read Full Article
    14. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (9 articles) Treatment
    2. (7 articles) MYCN
    3. (4 articles) Chemotherapy
    4. (3 articles) Immunotherapy
    5. (3 articles) Radiotherapy
  3. Recent Quotes

    1. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    2. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    3. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    4. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    5. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    6. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    7. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    8. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    9. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju
    10. The dBET1 and the dFKBP12 compounds are presently in a late stage of lead optimization for therapeutic development in both cancer and non-malignant diseases, Composition-of-matter and method-of-use patent applications have been filed on these and other additional targeted agents, as well as on the chemistry platform.
      By Prem Das